Left Atrial Deformation Imaging and Atrial Fibrillation in Patients with Rheumatic Mitral Stenosis

Jan Stassen, MD, Steele C. Butcher, MD, Farnaz Namazi, MD, Nina Ajmone Marsan, MD, PhD, Jeroen J. Bax, MD, PhD, and Victoria Delgado, MD, PhD, Leiden, The Netherlands; and Perth, Australia

Background: Atrial fibrillation (AF) is a frequent complication of rheumatic mitral stenosis (MS) and is associated with worse outcomes. Prediction of new-onset AF by assessing left atrial (LA) mechanics with speckle-tracking echocardiography might be useful for risk stratification and guiding therapeutic strategies. Therefore, the aim of this study was to assess the association of LA reservoir strain (LASr) and strain rate (LASRr) with AF at follow-up in patients with rheumatic MS.

Methods: Left atrial reservoir strain and LASRr measured by speckle-tracking echocardiography were assessed in 125 patients (mean age, 50 ± 15 years; 80.8% female) with rheumatic MS and without a history of AF. Patients were followed up for the occurrence of a first episode of AF after the index echocardiogram.

Results: During a median follow-up of 32 (9.5-70) months, 41 patients (32.8%) developed new-onset AF. Patients who developed AF had significantly more impaired LASr (13.4% ± 5.2% vs 18.9% ± 8.2%; P < .001) and LASRr (0.72 ± 0.26 s⁻¹ vs 0.98 ± 0.36 s⁻¹; P < .001) compared with patients who remained in sinus rhythm. On multivariable Cox regression analysis, LASr < 21% and LASRr < 0.8 s⁻¹/C₀ were independently associated with the development of AF at follow-up (hazard ratio = 7.03, 95% CI, 2.08-23.77, P = .002; and hazard ratio = 3.42, 95% CI, 1.59-7.34, P = .002, respectively).

Conclusions: LASr and LASRr are impaired in patients with rheumatic MS, and the degree of impairment is associated with new-onset AF at follow-up. (J Am Soc Echocardiogr 2022; - - - - .)

Keywords: Atrial fibrillation, Rheumatic mitral stenosis, Left atrial reservoir strain, Left atrial reservoir strain rate
been shown to be a useful diagnostic technique to predict the onset of AF and outcome in patients after AF ablation, cryptogenic stroke, and heart failure.4,12-15 However, the prognostic value of speckle-tracking echocardiography to assess LA strain in patients with rheumatic MS has not been thoroughly evaluated. Therefore, the aim of this study was to evaluate the association between LA strain assessed by speckle-tracking echocardiography and development of AF at follow-up in patients with rheumatic MS.

**METHODS**

**Patient Population**

A total of 259 patients with rheumatic MS referred for echocardiography at the Leiden University Medical Centre (Leiden, the Netherlands), from July 2000 until September 2020, were consecutively selected from an echocardiographic database. Patients with permanent AF or a history of paroxysmal AF, prior surgical mitral valve (MV) repair or replacement, suboptimal data to perform two-dimensional speckle-tracking echocardiography analysis, or lack of follow-up data were excluded. Demographic and clinical data were obtained from the departmental electronic medical record (EPD-vision; Leiden University Medical Centre). Echocardiographic data were analyzed retrospectively. The institutional review board (ECR) of the Leiden University Medical Centre waived the need for written patient informed consent as this study involved the retrospective analysis of clinically acquired data. The data that support the findings of this study are available on reasonable request to the corresponding author.

**Echocardiography**

Comprehensive transthoracic echocardiography was performed using Vivid 7, E9, or E95 ultrasound systems (GE Vingmed, Horten, Norway), equipped with a 3.5 MHz or M5S transducer, with the patient at rest in the left lateral decubitus position. Electrocardiogram (ECG)-triggered echocardiographic data were stored digitally in a cine-loop format for offline analysis (EchoPAC version 203, GE Vingmed Ultrasound, Horten, Norway). Left ventricular (LV) ejection fraction and LV end-diastolic and end-systolic volumes were calculated using the biplane Simpson’s method. Left atrial volumes were calculated from the apical four- and two-chamber views using the biplane method of disks and indexed to body surface area. Mitral stenosis severity was assessed with a multiparametric approach, according to contemporary guideline recommendations.4,13 Mitral valve area (MVA) was evaluated using the pressure half-time method and two-dimensional planimetry, whereas continuous-wave Doppler with the velocity-time integral of the MV was used to calculate the peak and mean transmitral gradient.4,13 Three beats in each view were analyzed and averaged. Concomitant valvular diseases were identified and graded as recommended, using a multiparametric approach based on qualitative, semiquantitative, and quantitative assessment.4,13-15 Right ventricular areas were measured from a focused right ventricular apical view.15 To assess right ventricular systolic function, tricuspid annular plane systolic excursion was measured on M-mode recordings of the lateral tricuspid annulus on a focused right ventricular apical view.16 The systolic pulmonary artery pressure was estimated based on the tricuspid regurgitant jet velocity, adding 3, 8, or 15 mm Hg based on the inferior vena cava diameter and collapsibility.17

**Speckle-Tracking Echocardiography**

Left atrial strain and strain rate were measured on the apical four-chamber view with the onset of the QRS complex used as the zero-reference point (R-R gating), according to current guidelines.18 According to a large meta-analysis, the guidelines recommend measuring LA strain from the apical four-chamber view.18,19 The mean frame rate was 60 ± 10 fps. A region of interest was manually drawn along the LA endocardial border when the LA was at its minimum volume after atrial contraction. Automatic tracking of the LA wall by the software was visually verified and corrected by adjusting the region of interest or the width of the contour, ensuring appropriate capture of LA motion. The resulting LA strain curve provided two peaks: one peak just before MV opening, representing LA reservoir strain (LASRr), and one peak just before atrial contraction, representing LA conduit strain (LASct). The difference between these two peaks represented the LA conduit strain (LAScd; Figure 1A). In addition, the peak (positive) strain rate during the reservoir phase, the peak (negative) strain rate during the conduit phase in early diastole, and the peak (negative) strain rate during LA contraction phase in late diastole were assessed from the strain rate curve and used to calculate the LASRr (LASRr), LAScd rate (LASRcd), and LASct rate (LASRct), respectively (Figure 1B). All values were determined using the averaged longitudinal strain and strain rate curves.

**Follow-up**

Serial follow-up at the outpatient clinic was obtained in all patients every 6-12 months and at any time the patient reported symptoms. At each examination, a standard 12-lead ECG was obtained and symptoms were noted. A 24-hour ECG Holter recording was performed if the patient had symptoms suggesting AF. Data were included up to the last date of follow-up. The endpoint of the study was the occurrence of new-onset AF from the first echocardiogram diagnosing rheumatic MS where LA strain was measured. Atrial fibrillation was documented on standard 12-lead ECG or on 24-hour ECG Holter recording in which AF was defined as irregular R-R intervals in the absence of distinct repeating P waves and irregular atrial activations for at least 30 seconds or during the entire 12-lead ECG.20

**Statistical Analysis**

Categorical variables are expressed as numbers and percentages. Normally distributed continuous variables are presented as mean ± SD, whereas nonnormally distributed variables are displayed as median and interquartile range. Categorical variables were compared using the Fisher’s exact test. Continuous variables were
compared using the independent-sample Student’s t test when normally distributed, whereas the Mann-Whitney U test was used to compare continuous variables that did not adhere to a normal distribution. The association between LASr and LASRr with the occurrence of the primary endpoint (new-onset AF) was assessed with fitted spline curves. The population was then divided in two groups based on the cutoff values of LASr and LASRr that were associated with an excess of new-onset AF (i.e., when the predicted hazard ratio (HR) was ≥1). Cumulative survival rates free of AF were calculated using the Kaplan-Meier method, and the log-rank test was used to compare groups. The association between clinical and echocardiographic variables and occurrence of new-onset AF was assessed using uni- and multivariable Cox proportional hazard regression models. Variables with a univariable value of \( P < .10 \) were incorporated into the multivariable models. The proportional hazards assumption was verified through the evaluation of Schoenfeld residuals. To incorporate nonlinearity in the fitted Cox regression models, as a sensitivity analysis, LASr and LASRr were entered as continuous variables according to the plateau regions of their respective fitted spline curves. To investigate the incremental value of LASr over LA volume index (LAVI), a likelihood ratio test was performed. The change in global \( \chi^2 \) values was calculated and reported. All tests were two sided, and \( P < .05 \) were considered statistically significant. Statistical analyses were performed using SPSS version 25.0 (IBM Corporation, Armonk, NY) and R version 4.0.1 (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

Of the 259 patients with rheumatic MS, 125 patients met the study inclusion criteria (Supplemental Figure 1). Demographic and clinical characteristics of the overall study population are summarized in Table 1. The mean age of the population was 50 ± 15 years, and 80.8% of the patients were female. A total of 23.9% of patients reported New York Heart Association functional class 3 or 4 heart failure symptoms, and 12% previously underwent percutaneous balloon mitral valvotomy. Table 2 summarizes the echocardiographic characteristics of the study population. Mitral valve peak and mean gradients were 16.0 ± 7.6 mm Hg and 8.3 ± 4.9 mm Hg, respectively. Mean MVA assessed by pressure half-time was 1.8 ± 0.8 cm²; 40.2% had severe MS (MVA ≤ 1.5 cm²).

During a median follow-up of 32 (9.5-70) months, 41 patients (32.8%) developed new-onset AF. Patients who developed new-onset AF during follow-up were more likely to be male (34.1% vs 11.9%, \( P = .007 \)) and had smaller MVA (1.6 ± 0.5 cm² vs 1.9 ± 0.9 cm², \( P = .031 \)) and larger end-diastolic LV volume index (73 [61-91] mL/m² vs 65 [51-82] mL/m², \( P = .020 \)) compared with patients who remained in sinus rhythm. There were no significant differences in age, heart failure symptoms, treatment with percutaneous balloon valvotomy, MV mean gradient, or LV ejection fraction. When assessing echocardiographic measurements of LA size and function, patients who developed AF during follow-up had

Figure 1  Assessment of LA strain (A) and LA strain rate (B). Panel A shows an LA strain curve providing two peaks: one peak just before MV opening, representing LASr, and one peak just before atrial contraction, representing LASct. The difference between these two peaks represents the LAScd. Panel B shows an LA strain rate curve providing three peaks: the positive peak representing LASRr, the early negative peak during early diastole representing LASRcd, and the second negative peak during late diastole, representing LASRct. Values are determined using the averaged longitudinal strain and strain rate curves (white dotted line).
### Table 1 Clinical and demographic characteristics

| Variable                  | Total population (N = 125) | AF (n = 41) | No AF (n = 84) | P value |
|---------------------------|-----------------------------|-------------|----------------|---------|
| Age, years                | 50 ± 15                     | 52 ± 14     | 49 ± 16        | .348    |
| Sex, female               | 101 (80.8)                  | 27 (65.9)   | 74 (88.1)      | .007    |
| Caucasian                 | 53 (46.1)                   | 18 (45.0)   | 35 (46.7)      | >.999   |
| BMI, kg/m²                | 25.6 ± 4.8                  | 25.9 ± 4.3  | 25.5 ± 5.0     | .647    |
| Hypertension              | 40 (32.8)                   | 11 (26.8)   | 29 (35.8)      | .415    |
| Dyslipidemia              | 22 (18.3)                   | 6 (14.6)    | 16 (20.3)      | .620    |
| DM                        | 22 (18.3)                   | 4 (9.8)     | 4 (4.9)        | .440    |
| CKD                       | 25 (22.9)                   | 9 (23.1)    | 16 (22.9)      | .979    |
| NYHA class ≥ 3           | 21 (23.9)                   | 5 (18.5)    | 16 (26.2)      | .598    |
| Previous PBMV            | 15 (12)                     | 3 (7.3)     | 12 (14.3)      | .382    |
| Beta blocker              | 50 (41.0)                   | 16 (39.0)   | 34 (42.0)      | .846    |
| ACEI or ARB               | 12 (9.8)                    | 3 (7.3)     | 9 (11.1)       | .749    |
| Diuretic                  | 45 (36.9)                   | 14 (34.1)   | 31 (38.3)      | .695    |
| Spironolactone            | 37 (30.3)                   | 12 (29.3)   | 25 (30.9)      | >.999   |
| Oral anticoagulation      | 19 (15.6)                   | 4 (9.8)     | 15 (18.5)      | .292    |

Values are presented as mean ± SD or n (%).

ACEI, Angiotensin II converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CCB, calcium channel blocker; CKD, chronic kidney disease (defined as eGFR < 60 mL/minute/1.73 m²); DM, diabetes mellitus; NYHA, New York Heart Association; PBMV, percutaneous balloon mitral valvotomy.

### Table 2 Standard echocardiographic characteristics

| Variable                  | Total population (N = 125) | AF (n = 41) | No AF (n = 84) | P value |
|---------------------------|-----------------------------|-------------|----------------|---------|
| Heart rate, bpm           | 77 ± 13                     | 75 ± 12     | 77 ± 13        | .343    |
| MV peak gradient, mm Hg   | 16.0 ± 7.6                  | 16.3 ± 7.5  | 15.8 ± 7.7     | .733    |
| MV mean gradient, mm Hg   | 8.3 ± 4.9                   | 8.8 ± 5.6   | 8.1 ± 4.6      | .475    |
| MVA by planimetry, cm²    | 1.9 ± 0.8                   | 1.7 ± 0.7   | 1.9 ± 0.8      | .369    |
| MVA by PHT, cm²           | 1.8 ± 0.8                   | 1.6 ± 0.5   | 1.9 ± 0.9      | .031    |
| MVA by PHT ≤ 1.5 cm²      | 49 (40.2)                   | 20 (48.8)   | 29 (35.8)      | .178    |
| Significant MR*           | 49 (39.2)                   | 15 (36.6)   | 34 (40.5)      | .701    |
| IVS end-diastolic thickness, mm | 10.0 ± 2.6                  | 10.2 ± 2.3  | 9.9 ± 2.7      | .543    |
| LV PW end-diastolic thickness, mm | 9.8 ± 3.1                  | 10.0 ± 2.2  | 9.7 ± 3.4      | .587    |
| LV end-diastolic diameter, mm | 48.9 ± 6.6                  | 50.0 ± 6.9  | 48.3 ± 6.3     | .185    |
| LV end-systolic diameter, mm | 34.2 ± 7.9                  | 34.2 ± 8.3  | 34.3 ± 7.7     | .953    |
| LV EDV index, mL/m²       | 67 (55-85)                  | 73 (61-91)  | 65 (51-82)     | .020    |
| LV ESV index, mL/m²       | 28 (21-37)                  | 31 (24-44)  | 28 (19-35)     | .063    |
| LV EF, %                  | 57 ± 10                     | 56 ± 9      | 57 ± 11        | .594    |
| Stroke volume index, mL/m² | 39 ± 10                     | 39 ± 9      | 39 ± 11        | .910    |
| Pulmonary arterial systolic pressure, mm Hg | 35.5 (30.0-46.3)            | 36.5 (25.8-52.8) | 35.0 (30.0-45.8) | .632    |
| RV EDA, cm²               | 19.1 ± 3.8                  | 20.0 ± 4.2  | 18.8 ± 3.5     | .107    |
| RV ESA, cm²               | 11.8 ± 3.2                  | 12.6 ± 4.1  | 11.5 ± 2.7     | .113    |
| TAPSE, mm                 | 22.9 ± 4.1                  | 22.0 ± 4.1  | 23.4 ± 4.0     | .068    |

Values are presented as mean ± SD, median (interquartile range), or n (%).

EDA, End-diastolic area; EDV, end-diastolic volume; EF, ejection fraction; ESA, end-systolic area; ESV, end-systolic volume; IVS, interventricular septum; LV, left ventricle; MR, mitral regurgitation; PHT, pressure half-time; PW, posterior wall; RV, right ventricle; TAPSE, tricuspid annular plane systolic excursion.

*Defined as moderate or severe MR.
Figure 2 Spline curves demonstrating the HR for the occurrence of AF at follow-up according to LASr (A) and LASRr (B). The curve in panel A shows the HR change for occurrence of AF at follow-up with 95% CIs (shaded blue areas) across a range of values of LASr at the time of the index echocardiogram. The curve in panel B shows the HR change for occurrence of AF at follow-up with 95% CIs (shaded blue areas) across a range of values of LASRr at the time of the index echocardiogram.

Table 3 Echocardiographic measurements of LA size and function

| Variable     | Total population (N = 125) | AF (n = 41) | No AF (n = 84) | P value |
|--------------|-----------------------------|-------------|----------------|---------|
| LAVI max, mL/m² | 59 ± 28                     | 129 ± 61    | 92 ± 35        | .001    |
| LAVI min, mL/m² | 43 ± 24                     | 55 ± 31     | 37 ± 18        | <.001   |
| LAEF, %      | 26.4 ± 20.1                 | 22.4 ± 21.3 | 28.3 ± 19.4    | .132    |
| LASr, %      | 17.1 ± 7.8                  | 13.4 ± 5.2  | 18.9 ± 8.2     | <.001   |
| LAScd, %     | −9.6 ± 5.4                  | −7.6 ± 3.6  | −10.6 ± 5.9    | .001    |
| LASct, %     | −8.1 ± 4.3                  | −6.5 ± 4.3  | −8.8 ± 4.2     | .01     |
| LASRr, s⁻¹   | 0.89 ± 0.35                 | 0.72 ± 0.26 | 0.98 ± 0.36    | <.001   |
| LASRcd, s⁻¹  | −0.58 ± 0.38                | −0.45 ± 0.21| −0.65 ± 0.43   | .01     |
| LASRct, s⁻¹  | −0.86 ± 0.22                | −0.65 ± 0.38| −0.95 ± 0.48   | .001    |

Values are presented as mean ± SD. LAEF, LA ejection fraction.)
a larger LAVI (129 ± 61 mL/m² vs 92 ± 5 mL/m², \(P = .001\)) and significantly more impaired LASr (13.4% ± 5.2% vs 18.9% ± 8.2%, \(P < .001\)) and LASRr (0.72 ± 0.26 s⁻¹ vs 0.98 ± 0.36 s⁻¹, \(P < .001\)) compared with patients who did not present with new-onset AF (Table 3).

**Association between LASr and LASRr and New-Onset AF**

Based on spline curve analysis, decreasing values of LASr and LASRr were associated with increasing HR of new-onset AF (Figure 2). Left atrial reservoir strain < 21% and LASRr < 0.8 s⁻¹ were associated with an excess risk of new-onset AF and were used to divide the population. On Kaplan-Meier analysis, patients with an LASr < 21% had a significant reduction in event-free survival for the occurrence of new-onset AF at follow-up compared with their counterparts (73.9% vs 100%, respectively, at 3 years of follow-up, \(P < .001\); Figure 3A). Likewise, patients with an LASRr < 0.8 s⁻¹ showed a significantly reduced event-free survival compared with patients with an LASRr ≥ 0.8 s⁻¹ (65.5% vs 93.6%, respectively, at 3 years of follow-up, \(P < .001\); Figure 3B).

On univariate analysis, age, sex, MVA by pressure half-time, LV end-diastolic volume, LAVI, LASr, and LASRr were significantly associated with the occurrence of new-onset AF (Table 4). Subsequently, several multivariable models were constructed with a maximum of

**Figure 3** Kaplan-Meier curves for occurrence of AF according to LASr (A) and LASRr (B). The Kaplan-Meier curves demonstrate the lower AF free survival rates at follow-up for patients with LASr < 21% (A) and LASRr < 0.8 s⁻¹ (B).
four variables incorporated to avoid overfitting. Multivariable Cox regression analyses showed that, after adjusting for age, LAVI and LV end-diastolic volume, LASr < 21% and LASRr < 0.8 s \(^{-1}\) remained significantly associated with the occurrence of AF at follow-up after adjusting for age, LAVI and LV end-diastolic volume (HR = 7.030; 95% CI, 2.079-23.771; \(P = .002\) for LASr < 21%; and HR = 3.417, 95% CI, 1.591-7.339; \(P = .002\) for LASRr < 0.8 s \(^{-1}\); Table 5). In a sensitivity analysis, these findings were confirmed using a second multivariable model adjusting for age, sex, and MVA (Table 5).

The models with LASr and LASRr as continuous variables can be found in Supplemental Table 1. Models with LASr and LASRr as continuous variables, accounting for the plateau regions of each fitted spline curve (Figure 2A and 2B), can be found in Supplemental Table 2.

To determine the incremental prognostic value of LASr over LA volume, a likelihood ratio test was performed. The addition of LASr to a baseline model with LAVI showed a significant increase in the \(\chi^2\) value (\(\chi^2\) difference = 14.1, \(P < .001\)), demonstrating the incremental prognostic value of LASr in patients with rheumatic MS.

### DISCUSSION

The main findings of this study can be summarized as follows: (1) LASr and LASRr are independently associated with the development of AF during follow-up in patients with rheumatic MS, and (2) patients with an LASr < 21% and LASRr < 0.8 s \(^{-1}\) show a significant reduction in event-free survival for the occurrence of new-onset AF at follow-up.

### Pathophysiology of AF in Patients with MS

In MS, the combination of an increase in LA pressure and an intense atrial inflammatory response secondary to the underlying rheumatic carditis is accompanied by a progressive increase in interstitial fibrosis of the atrial wall with disorganization of atrial muscle bundles, LA dysfunction, and eventually LA dilatation.\(^{21,22}\) Atrial remodeling alters atrial electrical properties, enhancing the risk of AF development.\(^{\ast}\) New-onset AF is associated with poor outcomes in patients with rheumatic MS since AF may further impair LA function and abruptly increase LA pressures that lead to pulmonary edema,

| Table 4 Univariable Cox proportional hazard models for occurrence of AF at follow-up |
|---------------------------------|---|---|---|
| **Clinical and demographic characteristics** | **HR (95% CI)** | **P value** |
| Age | 1.043 (1.018-1.068) | .001 |
| Sex, female | 0.503 (0.261-0.970) | .040 |
| BMI | 1.040 (0.965-1.120) | .307 |
| Hypertension | 1.002 (0.497-2.017) | .997 |
| Dyslipidemia | 1.219 (0.505-2.947) | .660 |
| DM | 1.298 (0.772-2.182) | .325 |
| **Echocardiographic characteristics** | **HR (95% CI)** | **P value** |
| MV mean gradient | 1.045 (0.976-1.119) | .210 |
| MVA by PHT | 0.550 (0.277-1.095) | .089 |
| LV EDV | 1.007 (1.001-1.012) | .016 |
| LV EF | 0.993 (0.958-1.029) | .696 |
| **Echocardiographic measurements of LA size and function** | **HR (95% CI)** | **P value** |
| LAVI | 1.007 (1.000-1.015) | .065 |
| LASr | 0.911 (0.866-0.958) | <.001 |
| LASRr | 0.036 (0.008-0.156) | <.001 |
| LASr < 21% | 8.204 (2.514-26.774) | <.001 |
| LASRr < 0.8 s \(^{-1}\) | 3.473 (1.806-6.767) | <.001 |

*BMI, Body mass index; DM, diabetes mellitus; EDV, end-diastolic volume; EF, ejection fraction; LV, left ventricle; PHT, pressure half-time.*

| Table 5 Multivariable Cox proportional hazard models for occurrence of AF at follow-up |
|---------------------------------|---|---|---|---|--- |
| **Multivariable analysis adjusting for age, LAVI, and LVEDV** | **Multivariable analysis adjusting for age, sex, and MVA by PHT** | **HR (95% CI)** | **P value** | **HR (95% CI)** | **P value** |
| LASr < 21% | 7.030 (2.079-23.771) | .002 | 8.588 (2.507-29.424) | .001 |
| LASRr < 0.8 s \(^{-1}\) | 3.417 (1.591-7.339) | .002 | 3.273 (1.648-6.501) | .001 |

*LVEDV, LV end-diastolic volume; PHT, pressure half-time.*
pulmonary hypertension, and eventually right ventricle dysfunction. The pathophysiology of MS differs from most other valvar diseases, as it typically causes an isolated increase in LA afterload with much less impact on the left ventricle. Therefore, it seems essential to assess the LA dimension and function to improve risk stratification and optimize the timing of intervention in these patients. Although previous studies have demonstrated the relationship between LA size and AF occurrence, LA dysfunction may represent an earlier stage of LA remodeling than LA dilation alone. Moreover, LASr more accurately reflects dynamic LV filling pressures, whereas LA size reflects the chronic effects of LV filling pressures over time. Left atrial reservoir function also correlates better with LA fibrosis and compliance than LA conduit and contractile function do since these functions are also influenced by LV relaxation and intrinsic atrial contractility, respectively. Finally, as the extent of atrial fibrosis quantified by late gadolinium enhancement on cardiac magnetic resonance imaging correlates well with LASr measured by speckle-tracking echocardiography, LA could be a good surrogate of atrial fibrosis and could therefore be useful in the risk stratification of patients with rheumatic MS.

Risk Assessment of AF in Patients with Rheumatic MS

As AF is the most prevalent arrhythmia with a significant health and socioeconomic impact, increasing attention has been given to the development of prediction models for assessing the risk of new-onset AF, both for the general population and for subgroups of patients with an underlying cardiovascular disease. Previous studies have demonstrated that LASr is associated with the development of AF after cryptogenic stroke or catheter ablation and in patients with heart failure. The results in the current study demonstrate that impaired values of LASr and LASRr are also associated with an increased risk of developing AF at follow-up in patients with rheumatic MS. In addition, LASr < 21% and LASRr < 0.8 s⁻¹ are independently associated with incident AF at follow-up. Interestingly, none of the patients with an LASr ≥ 21% developed AF during the first 5 years of follow-up. In another study including 101 asymptomatic patients with mild or moderate rheumatic MS followed up for 4 years, demonstrated that assessment of LA strain was more accurate than other clinical and echocardiographic parameters for predicting the development of new-onset AF. Patients with asymptomatic MS and an LASr > 17.4% showed a reduced incidence of new-onset AF compared with those with an LASr ≤ 17.4%. In a 5-year follow-up study of 81 asymptomatic patients with mild or moderate rheumatic MS, demonstrated similar results, defining LASr < 16.5% as an optimal cutoff value to predict new-onset AF. Differences in patient populations may explain the different reported cutoff values of LASr associated with new-onset AF.

Clinical Implications

The global burden of RHD remains significant, and 80% of strokes in patients with RHD occur in patients with rheumatic MS and AF. It is estimated that approximately 30%-40% of patients with symptomatic MS develop AF, which is in accordance with the results of our study, where 32.8% of patients developed AF during a median follow-up of 32 months. The presence of AF in patients with rheumatic MS is associated with a poor prognosis, due to an association with an increased risk of thromboembolic events, heart failure, and premature death, even after valve intervention. Therefore, strategies for reducing the incidence of AF in these patients are needed but complicated by the fact that RHD is largely limited to populations with little access to primary health care. Echocardiography is an accessible imaging technique that, according to the results of this study, may help to timely identify patients with rheumatic MS at risk of developing AF and who therefore need closer follow-up. In this regard, assessment of LASr may clinically be more comprehensive than assessment of LASRr. The strength of our study is the identification of a subgroup of patients who have a very low risk of developing AF during the first years of follow-up (none of the patients with an LASr ≥ 21% developed AF during the first 5 years of follow-up) and in whom the need for anticoagulant treatments can be delayed, whereas the group with an increased risk of developing AF needs close monitoring to implement timely anticoagulant therapy.

Other echocardiographic methods to assess LA function (such as LA expansion index) may also identify patients at risk of developing AF. However, the prognostic value of these novel measurements of LA function have not been investigated in patients with rheumatic MS and therefore requires further research.

Limitations

This study is subject to the limitations of its retrospective, single-center, observational design. A time span of 20 years was used to retrospectively identify patients to acquire the large cohort as presented. Images were not recorded specifically for assessment of LA function (in terms of orientation, depth, gain, and frame rate), potentially influencing the results. In addition, although comprehensive follow-up for new-onset AF was performed, without continuous ECG monitoring it is possible to have missed the development of cases of asymptomatic AF during follow-up. However, because dia stolic filling time is significantly reduced with new-onset AF, it is unlikely that many patients with significant MS would have remained asymptomatic. Finally, although this is the largest study on this topic in current literature, the small sample size does limit the power of our conclusions. Larger studies are therefore needed to confirm our data.

CONCLUSION

Left atrial strain is abnormal in patients with rheumatic MS, and the degree of impairment is associated with the development of AF at follow-up.

SUPPLEMENTARY DATA

Supplementary data related to this article can be found at https://doi.org/10.1016/j.jecho.2021.12.010.

REFERENCES

1. Watkins DA, Johnson CO, Colquhoun SM, Karthikeyan G, Beaton A, Bukhman G, et al. Global, regional, and national burden of rheumatic heart disease, 1990-2015. N Engl J Med 2017;377:713-22.
2. Zühlke L, Engel ME, Karthikeyan G, Rangarajan S, Mackie P, Cupido B, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur Heart J 2015;36:1115-22.
3. Jung B, Vahanian A. Epidemiology of acquired valvular heart disease. Can J Cardiol 2014;30:962-70.
4. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2021;143:e72-227.

5. Zühlke L, Karthikeyan G, Engel ME, Rangarajan S, Mackie P, Cupido Katyia Mauff B, et al. Clinical outcomes in 3343 children and adults with rheumatic heart disease from 14 low- and middle-income countries: two-year follow-up of the global Rheumatic Heart Disease Registry (the REMEDY study). Circulation 2016;134:1456-66.

6. Wang B, Xu ZY, Han L, Zhang GX, Lu FL, Song ZG. Impact of preoperative atrial fibrillation on mortality and cardiovascular outcomes of mechanical mitral valve replacement for rheumatic mitral valve disease. Eur J Cardiothorac Surg 2013;43:513-9.

7. Karthikeyan G, Connolly SJ, Yusuf S. Overestimation of stroke risk in rheumatic mitral stenosis and the implications for oral anticoagulation. Circulation 2020;142:1697-9.

8. Thomas L, Muraru D, Popescu BA, Siges M, Rosca M, Pedrizetti G, et al. Evaluation of left atrial size and function: relevance for clinical practice. J Am Soc Echocardiogr 2020;33:934-52.

9. Kuppalahy SS, Akoum N, Burgon NS, Badger TJ, Kholmovski EG, Vijayakumar S, et al. Left atrial strain and strain rate in patients with paroxysmal and persistent atrial fibrillation: relationship to left atrial structural remodeling detected by delayed-enhancement MRI. Circ Cardiovasc Imaging 2018;11:231-9.

10. Motoki H, Negishi K, Kusunose K, Popovic ZB, Bhargava M, Wazni OM, et al. Global left atrial strain in the prediction of sinus rhythm maintenance after catheter ablation for atrial fibrillation. J Am Soc Echocardiogr 2014;27:1184-92.

11. Pathan F, Sivaraj E, Negishi K, Rafiudeen R, Pathan S, D’Elia N, et al. Use of atrial strain to predict atrial fibrillation after cerebral ischemia. JACC Cardiovascular Imaging 2018;11:1557-65.

12. Park JJ, Park JH, Hwang IC, Park JB, Cho GY, Marwick TH. Left atrial strain as a predictor of new-onset atrial fibrillation in patients with heart failure. JACC Cardiovascular Imaging 2020;13:2071-81.

13. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009;22:1-23.

14. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2017;38:2739-91.

15. Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. Recommendations for noninvasive evaluation of native valves: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2017;30:303-71.

16. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;1:1-39.

17. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010;23:685-713. quiz 86-88.

18. Badano LP, Kolas TJ, Muraru D, Abraham TP, Aurigemma G, Edvardsen T, et al. Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: a consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging 2018;19:591-600.

19. Pathan F, D’Elia N, Nolan MT, Marwick TH, Negishi K. Normal ranges of left atrial strain by speckle-tracking echocardiography: a systematic review and meta-analysis. J Am Soc Echocardiogr 2017;30:59-70.e8.

20. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021;42:373-498.

21. Boldt A, Wetzel U, Lauschke J, Weigl J, Gummett J, Hindricks G, et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 2004;90:400-5.

22. Her AJ, Choi EY, Shim CY, Song BW, Lee S, Ha JW, et al. Prediction of left atrial fibrillation with speckle tracking echocardiography in mitral valve disease: a comparative study with histopathology. Korean Circ J 2012;42:311-8.

23. Pellman J, Lyon RC, Sheikh F. Extracellular matrix remodeling in atrial fibrillation: mechanisms and implications in atrial fibrillation. J Mol Cell Cardiol 2010;48:461-7.

24. Probst P, Goldschlager N, Selzer A. Left atrial size and atrial fibrillation in mitral stenosis. Factors influencing their relationship. Circulation 1973;48:1282-7.

25. Bhargava M, Wazni OM, Kalsi AM, Negishi K, Cooper M, Dada S, et al. Extracellular matrix remodeling detected by delayed-enhancement MRI. Circ Cardiovasc Imaging 2010;3:231-9.

26. Keren G, Etzion T, Sherez J, Zelcer AA, Megidish R, Miller IH, et al. Atrial fibrillation and atrial enlargement in patients with mitral stenosis. Am Heart J 1987;114:1146-55.

27. Anné W, Willems R, Roskams T, Sergeant P, Herijgers P, Hohlemans P, et al. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation. Cardiovasc Res 2005;67:655-66.

28. Mondillo S, Cameli M, Caputo ML, Lisi M, Palmerini E, Padeletti M, et al. Early detection of left atrial strain abnormalities by speckle-tracking in hypertensive and diabetic patients with normal left atrial size. J Am Soc Echocardiogr 2011;24:898-908.

29. Cameli M, Sparla S, Loisito M, Righini FM, Merci D, Lisi M, et al. Correlation of left atrial strain and Doppler measurements with invasive measurement of left ventricular end-diastolic pressure in patients stratified for different values of ejection fraction. Echocardiography 2016;33:398-405.

30. Chung MK, Refaat M, Shen WK, Kutyifa V, Cha YM, Di Biase L, et al. Atrial fibrillation: JACC Council perspectives. J Am Coll Cardiol 2020;75:1689-713.

31. Ancora R, Comenale Pinto S, Caso P, Di Salvo G, Severino S, D’Andrea A, et al. Two-dimensional atrial systolic strain imaging predicts atrial fibrillation at 4-year follow-up in asymptomatic rheumatic mitral stenosis. J Am Soc Echocardiogr 2013;26:270-7.

32. Candan O, Gecmen C, Kalayci A, Dogan C, Bayam E, Ozkan M. Left atrial electromechanical conduction time predicts atrial fibrillation in patients with mitral stenosis: a 5-year follow-up speckle-tracking echocardiography study. Int J Cardiovasc Imaging 2017;33:1491-501.

33. Kumar RK, Antunes MJ, Beaton A, Mirabel M, Nkomo VT, Okello E, et al. Contemporary diagnosis and management of rheumatic heart disease: implications for closing the gap: a scientific statement from the American Heart Association. Circulation 2020;142:e337-57.

34. Hsiao SH, Chiu K. Left atrial expansion index predicts atrial fibrillation in dyspnea. Circ J 2013;77:2712-21.

35. Wang WH, Hsiao SH, Lin KL, Wu CJ, Kang PL, Chiu KR. Left atrial expansion index for predicting atrial fibrillation and in-hospital mortality after coronary artery bypass graft surgery. Ann Thorac Surg 2012;93:796-803.
Supplemental Figure 1  Study flow chart. 2D-STE, Two-dimensional speckle-tracking echocardiography; LUMC, Leiden University Medical Center.
Supplemental Table 1  Multivariable Cox proportional hazard models for occurrence of AF at follow-up with LASr and LASRr entered as continuous variables

|                      | Multivariable analysis adjusting for age, LAVI, and LVEDV | Multivariable analysis adjusting for age, sex, and MVA |
|----------------------|----------------------------------------------------------|----------------------------------------------------------|
|                      | HR (95% CI) | P value | HR (95% CI) | P value |
| LASr                 | 0.894 (0.837-0.955) | .001 | 0.918 (0.872-0.967) | .001 |
| LASRr                | 0.066 (0.013-0.329) | .001 | 0.052 (0.012-0.224) | <.001 |

LVEDV, LV end-diastolic volume; PHT, pressure half-time.

Supplemental Table 2  Multivariable Cox proportional hazard models for occurrence of AF at follow-up with LASr and LASRr entered as continuous variables, accounting for nonlinearity

|                      | Multivariable analysis adjusting for age, LAVI, and LVEDV | Multivariable analysis adjusting for age, sex, and MVA |
|----------------------|----------------------------------------------------------|----------------------------------------------------------|
|                      | HR (95% CI) | P value | HR (95% CI) | P value |
| LASr, per %, above 18%* | 0.702 (0.552-0.894) | .004 | 0.685 (0.542-0.865) | .002 |
| LASRr, per s^-1, up to 1.1 s^-1* | 0.031 (0.005-0.185) | <.001 | 0.027 (0.005-0.137) | <.001 |

LVEDV, LV end-diastolic volume; PHT, pressure half-time.

*To incorporate nonlinearity in the fitted Cox regression models, both LASr and LASRr were treated as continuous variables while accounting for the plateau regions of each fitted spline curve (Figure 2A and 2B, extending from <18% for values of LASr and >1.1 s^-1 for values of LASRr, respectively). For LASr, the HR was estimated per %, above values of LASr of 18%. Likewise, the HR for LASRr was estimated per s^-1, up to a maximum of 1.1 s^-1.